| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4673951 | A | Permeability of the compound | 1 | ALA4673208 | assay format | Scientific Literature | ||
| 2. | ALA4673952 | P | Solubility of the compound | 1 | ALA4673208 | small-molecule physicochemical format | Scientific Literature | ||
| 3. | ALA4673956 | A | AUC (0 to t) in Sprague-Dawley rat at 15.5 mg/kg, po via gavage measured up to 48 hrs by HPLC analysis | Rattus norvegicus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 4. | ALA4673957 | A | Cmax in Sprague-Dawley rat at 15.5 mg/kg, po via gavage measured up to 48 hrs by HPLC analysis | Rattus norvegicus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 5. | ALA4673958 | A | Half life in Sprague-Dawley rat at 15.5 mg/kg, po via gavage measured up to 48 hrs by HPLC analysis | Rattus norvegicus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 6. | ALA4673964 | F | Antifibrotic activity in mouse MES-13 cells assessed as decrease in glucose-induced fibronectin protein level at 24.5 mol/L pretreated with glucose for 48 hrs followed by compound treatment relative to control | Mus musculus | 1 | ALA4673208 | cell-based format | Scientific Literature | |
| 7. | ALA4673965 | F | Antifibrotic activity in mouse MES-13 cells assessed as decrease in glucose-induced CTGF protein level at 24.5 mol/L pretreated with glucose for 48 hrs followed by compound treatment relative to control | Mus musculus | 1 | ALA4673208 | cell-based format | Scientific Literature | |
| 8. | ALA4673966 | F | Antifibrotic activity in mouse MES-13 cells assessed as decrease in TGFbeta1-induced fibronectin protein level pretreated with TGFbeta1 for 48 hrs followed by compound treatment | Mus musculus | 3 | ALA4673208 | cell-based format | Scientific Literature | |
| 9. | ALA4673967 | F | Antifibrotic activity in mouse MES-13 cells assessed as decrease in TGFbeta1-induced CTGF protein level pretreated with TGFbeta1 for 48 hrs followed by compound treatment | Mus musculus | 3 | ALA4673208 | cell-based format | Scientific Literature | |
| 10. | ALA4673968 | F | Antifibrotic activity in rat NRK-52E cells assessed as up regulation of TGF-beta1 inhibited E-cadherin protein expression pretreated with TGFbeta1 for 48 hrs followed by compound treatment by immunoblotting analysis | Rattus norvegicus | 1 | ALA4673208 | cell-based format | Scientific Literature | |
| 11. | ALA4673969 | F | Antifibrotic activity in rat NRK-52E cells assessed as decrease in TGFbeta1-induced alpha-SMA protein expression pretreated with TGFbeta1 for 48 hrs followed by compound treatment by immunoblotting analysis | Rattus norvegicus | 1 | ALA4673208 | cell-based format | Scientific Literature | |
| 12. | ALA4673971 | F | Antifibrotic activity in rat NRK-52E cells assessed as decrease in TGFbeta1-induced cellular morphological changes at 24.5 mol/L measured after 24 hrs | Rattus norvegicus | 1 | ALA4673208 | cell-based format | Scientific Literature | |
| 13. | ALA4673972 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as decrease in glomerular sclerosis lesions by measuring glomerular sclerosis index at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by PAS staining based optical microscopic analysis relative to control | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 14. | ALA4673975 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as urine albumin to creatinine ratio at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 2.72 +/- 0.729 ug/mg) | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 15. | ALA4673976 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as urinary albumin level at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 244.98 +/- 44.98 ug) | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 16. | ALA4673977 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as creatinine clearance rate at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 120.77 +/- 20.77 uL/min) | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 17. | ALA4673978 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as serum creatinine level at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 38.86 +/- 8.86 mmol/L) | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 18. | ALA4673979 | F | Antidiabetic nephropathy in 8 weeks old db/db mouse model assessed as blood urea nitrogen level at 40 mg/kg, po via gavage administered once a day for 24 weeks of age and measured 24 hrs post last dose by ELISA (Rvb = 11.22 +/- 1.22 mmol/L) | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 19. | ALA4673990 | T | Acute toxicity in po dosed KM mouse measured within 14 days | Mus musculus | 1 | ALA4673208 | organism-based format | Scientific Literature | |
| 20. | ALA4673991 | F | Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay | Mus musculus | 19 | ALA4673208 | cell-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!